Key facts
- Alzprotect’s last known valuation is $67.8M (Jun 2025).
- It has raised $48.0M.
- Notable investors include Siparex, Finovam Gestion, Fondation de l'Université de Lille, Michael J. Fox Foundation, Nord France Amorçage — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Alzprotect
- ·The full record, as it builds
Funding rounds
No funding rounds for Alzprotect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alzprotect
Operator of a biotechnology company intended to specialize in neurodegeneration and tauopathies. The company focuses its research on tauopathies where neuronal degeneration is the consequence of the abnormal aggregation of hyperphosphorylated Tau proteins combined with inflammation, enabling doctors to have drug candidates for the treatment of neurodegenerative diseases including Alzheimer's disease and orphan tauopathies such as Progressive Supranuclear Palsy.
- Sector
- Healthcare
- HQ
- Loos, France
- Founded
- 2007
- Employees
- 8
- Website
- alzprotect.com/
- Ownership
- Privately Held (backing)
Alzprotect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alzprotect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alzprotect in its N-PORT filings yet. We sweep new filings monthly.